Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Selling, General & Admin	29.37	30.09	21.91	15.66	11.29
Research & Development	9.16	11.91	14.82	17.66	12.24
Operating Expenses	38.53	42	36.73	33.32	23.53
Operating Income	-38.53	-42	-36.73	-33.32	-23.53
Interest Expense	-0.27	-	-	-	-0.01
Interest & Investment Income	0.11	0.76	1.18	0.25	0.26
EBT Excluding Unusual Items	-38.68	-41.24	-35.55	-33.06	-23.28
Gain (Loss) on Sale of Assets	-	2.39	3.59	-	-
Other Unusual Items	-	-	-	-	0.23
Pretax Income	-38.68	-38.85	-31.97	-33.06	-23.05
Income Tax Expense	1.06	0.58	0.58	0.58	-
Earnings From Continuing Operations	-39.74	-39.43	-32.54	-33.64	-23.05
Minority Interest in Earnings	2.31	0.29	-	-	-
Net Income	-37.43	-39.14	-32.54	-33.64	-23.05
Preferred Dividends & Other Adjustments	-	1.05	1.15	-	1.45
Net Income to Common	-37.43	-40.19	-33.69	-33.64	-24.51
Shares Outstanding (Basic)	11	7	6	6	4
Shares Outstanding (Diluted)	11	7	6	6	4
Shares Change (YoY)	64.49%	11.16%	3.57%	34.52%	177.28%
EPS (Basic)	-3.38	-5.97	-5.57	-5.76	-5.64
EPS (Diluted)	-3.38	-5.97	-5.57	-5.76	-5.64
Free Cash Flow	-26.55	-28.2	-29.06	-28.36	-24.26
Free Cash Flow Per Share	-2.40	-4.19	-4.80	-4.85	-5.58
EBITDA	-38.52	-41.99	-36.73	-33.31	-23.53
D&A For EBITDA	0	0	0	0	0
EBIT	-38.53	-42	-36.73	-33.32	-23.53

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q